<p><i><strong>IRB approval on track as scheduled</strong></i></p><p><i><strong>Next step is obtaining all regulatory approvals, followed by site initiation visit</strong></i></p><p><i><strong>VELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies</strong></i></p>

<p><i><strong>Prioritizing VELDONA&reg;'s development for oral warts in HIV+ patients and Sjogren's syndrome</strong></i></p><p><i><strong>Burgeoning pet care market also presents growth opportunities for VELDONA&reg;</strong></i></p>

<p><i><strong>Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots</strong></i></p><p><i><strong>VELDONA^&reg; low-dose oral interferon technology demonstrates huge potential in in viral, autoimmune, and veterinary treatments</strong></i></p>

<p><i><strong>Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretion Ainos aims to complete all regulatory approvals for the study in Q4 2024</strong></i></p>

<p><i><strong>Ainos Plans To Conduct the Study at National Taiwan University Hospital, a Premier Taiwanese Medical Center for HIV Management</strong></i></p><p><i><strong>The U.S. FDA Have Granted Orphan Drug Designation (ODD) for the Company's VELDONA^&reg; Low-Dose Oral Interferon Formulation as a Potential Treatment for Oral Warts in HIV-Positive Patients</strong></i></p>

<p><i><strong>This patent marks a major leap in Ainos' antiviral research, contributing to global efforts against coronavirus infections</strong></i></p>